Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Angiology
Anti-SDF-1 treatment prevents retinal neovascularization in nonhuman primates, study shows
March 24th, 2006
RegenMed, a development-stage biotechnology company, announced that the company's anti-SDF-1 treatment prevents retinal neovascularization, a condition that causes blood vessels in the retina to leak fluid or blood and grow branches and scar tissue. This can lead to blurred, distorted vision in primates. The findings from the nonhuman primate SDF-1 antibody studies were presented by RegenMed researcher Edward Scott at the Bascom Palmer Eye Institute sponsored Angiogenesis meeting for clinical developments in the area of eye disease. RegenMed is advancing regenerative medicine by developing a broad adult stem cell platform for the prevention and...
Source: Drug Week (2006-03-24)
|
